Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 593 Cyclophosphamide 539 Magnetic Resonance Spectroscopy 527 Radiotherapy 506 Specimen Handling 504 Nivolumab 406 Cisplatin 370 Carboplatin 360 Biopsy 306 Blood Specimen Collection 296 Radiosurgery 284 Paclitaxel 276 Surveys and Questionnaires 269 Standard of Care 267 Gemcitabine 266 fludarabine 261 Dexamethasone 258 Drug Therapy 256 Bevacizumab 248 venetoclax 247 Oxaliplatin 206 Rituximab 197 Capecitabine 194 Radiation 190 Fluorouracil 186 Ipilimumab 183 durvalumab 181 Doxorubicin 174 atezolizumab 172 Etoposide 171

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × DLL3 protein, human × 1 year × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡